T-Structured Compounds Disrupting PI3Kα–RAS Interaction With Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors for treating cancers, particularly those targeting the PI3Kα isoform, face limitations such as intolerable toxicity and drug resistance, primarily due to hyperglycemia and hyperinsulinemia, which are on-target effects of inhibiting the PI3K/AKT pathway.
Innovation Solution
Development of compounds that disrupt the interaction between PI3Kα and small GTPases like Rac1, CDC42, or RAS proteins without significantly inhibiting the kinase activity of PI3Kα, thereby avoiding the toxic side effects associated with traditional PI3K inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional ATP-competitive PI3K kinase inhibitors are used, then PI3K activity is inhibited, but intolerable toxicity and drug resistance occur due to hyperglycemia and hyperinsulinemia
Solution Approach 1:
The invention segments the PI3K inhibition mechanism into two distinct approaches: (1) traditional ATP-competitive kinase inhibition that blocks all PI3K activity, and (2) selective disruption of the PI3Kα-RAS protein interaction that targets only oncogenic signaling. This segmentation allows the therapeutic agent to inhibit tumor growth while preserving normal metabolic functions, thereby reducing toxicity and side effects.
Solution Approach 2:
The therapeutic agent exhibits local quality by selectively disrupting the interaction between PI3Kα and small GTPases (RAS proteins) in tumor cells while leaving the kinase activity of PI3Kα intact in normal cells. This selective disruption targets the specific oncogenic pathway without affecting normal metabolic regulation, thus achieving tumor-specific therapy with reduced systemic toxicity.
2Reliability
If PI3Kα kinase activity is strongly inhibited, then tumor growth is suppressed, but hyperglycemia and hyperinsulinemia occur as on-target effects
Solution Approach 1:
The invention extracts the specific pathological interaction (PI3Kα-RAS protein binding) from the overall PI3K signaling pathway. By designing the therapeutic agent to specifically disrupt this interaction while leaving other PI3K functions intact, the patent eliminates the harmful on-target effects (hyperglycemia and hyperinsulinemia) that result from broad kinase inhibition, while maintaining anti-tumor activity.
Solution Approach 2:
Instead of inhibiting PI3Kα kinase activity directly (the conventional approach), the invention inverts the strategy by targeting the protein-protein interaction interface between PI3Kα and RAS proteins. This inverted approach achieves tumor suppression through a different mechanism that does not trigger the metabolic side effects associated with traditional kinase inhibition.
3Reliability
If broad-spectrum PI3K inhibition is applied, then multiple signaling pathways are blocked, but drug resistance develops and tolerance is reduced
Solution Approach 1:
The therapeutic agent provides dynamic and reversible disruption of the PI3Kα-RAS interaction, allowing for adjustable therapeutic effects. The agent can be administered at flexible dosages and can be combined with other therapies, enabling adaptive treatment strategies that can overcome or prevent drug resistance development while maintaining therapeutic response.
Data Source
AI summary
Provided herein are compounds and compositions thereof that may be capable of disrupting, interrupting, and/or preventing an interaction between a small GTPase protein and a PI3K protein (e.g., PI3Ka). The present disclosure also provides methods of treating cancers and other indications with such compounds or compositions thereof.